SanBio Company Limited (TYO:4592)

Japan flag Japan · Delayed Price · Currency is JPY
2,166.00
+91.00 (4.39%)
At close: Mar 6, 2026
Market Cap169.02B +148.5%
Revenue (ttm)n/a
Net Income-3.44B
EPS-48.26
Shares Out78.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,035,300
Average Volume1,373,915
Open2,075.00
Previous Close2,075.00
Day's Range2,034.00 - 2,195.00
52-Week Range1,053.00 - 3,990.00
Beta0.03
RSI54.26
Earnings DateMar 16, 2026

About SanBio Company

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company’s research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 29
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4592
Full Company Profile

Financial Performance

Financial Statements